Joinn Laboratories (China) Co Ltd
Company Profile
Business description
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
Contact
A5 Rongjing East Street
Beijing Economic-Technological Development Area
Beijing100176
CHNT: +86 1067869966
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
2,649
Stocks News & Analysis
stocks
Ask the Analyst: Why are ASX gold miners overvalued despite a near record gold price?
stocks
Chart of the Week: Looking past the oil shock to find consumer opportunities
stocks
ASX data center player sells US assets to bolster balance sheet
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,107.00 | 36.90 | 0.41% |
| CAC 40 | 8,210.37 | 89.05 | -1.07% |
| DAX 40 | 24,671.54 | 247.15 | -0.99% |
| Dow JONES (US) | 49,866.96 | 43.63 | -0.09% |
| FTSE 100 | 10,289.70 | 148.96 | -1.43% |
| HKSE | 26,626.28 | 412.50 | 1.57% |
| NASDAQ | 25,979.25 | 140.31 | 0.54% |
| Nikkei 225 | 62,833.84 | 3,320.72 | 5.58% |
| NZX 50 Index | 13,270.61 | 125.42 | 0.95% |
| S&P 500 | 7,377.70 | 12.58 | 0.17% |
| S&P/ASX 200 | 8,878.10 | 32.70 | 0.37% |
| SSE Composite Index | 4,180.09 | 19.92 | 0.48% |